Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 3Phase 3 2Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Part1: Advanced B-cell Malignancies 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Immunoproliferative Disorders 1Immune System Diseases 1COVID-19 1

Interventions

Cyclophosphamide 61Rituximab 60Etoposide 28fludarabine phosphate 23Prednisone 23fludarabine 22Vincristine 19Filgrastim 19Doxorubicin 19ibrutinib 16Peripheral Blood Stem Cell Transplantation 16venetoclax 15Lenalidomide 14Bortezomib 14Carboplatin 13CT-P10 13Gemcitabine 12Vorinostat 11Cytarabine 11pembrolizumab 9Radiotherapy 9Melphalan 9Magnetic Resonance Spectroscopy 9Dexamethasone 9Bendamustine Hydrochloride 9Paclitaxel 8Ifosfamide 8Cyclosporine 8Biopsy 8Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large B-Cell, Diffuse × acalabrutinib × Clear all
NCT02112526 2024-12-20

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Acerta Pharma BV

Phase 1 Completed
21 enrolled 11 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03527147 2022-08-15

PRISM

Acerta Pharma BV

Phase 1 Completed
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡